Achillion to Present at the 2013 Leerink Swann Global Healthcare Conference

Fri Feb 8, 2013 6:55am EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130208:nGNXUXDBYa

NEW HAVEN, Conn., Feb. 8, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN)
announced today that Michael Kishbauch, President and Chief Executive Officer of Achillion, will
present a corporate update at the Leerink Swann Global Healthcare Conference on Wednesday,
February 13, 2013 at 3:30 p.m. EST at the Waldorf-Astoria Hotel in New York, NY.

The live audio and video broadcast and the subsequent archived webcasts of the Company's
presentations will be available on the Company's website, http://www.achillion.com
http://www.globenewswire.com/newsroom/ctr?d=10021101&l=2&u=http%3A%2F%2Fwww.achillion.com , under
the "News Center" section. The audio recording will be archived for 30 days following the live
presentation. Please connect to Achillion's website several minutes prior to the start of the
presentation to ensure adequate time for any software downloads that may be necessary.

About Achillion Pharmaceuticals

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments
to patients with infectious disease. Achillion's proven discovery and development teams have
advanced multiple product candidates with novel mechanisms of action. Achillion is focused on
solutions for the most challenging problems in infectious disease including the hepatitis C virus
(HCV) and resistant bacterial infections. For more information on Achillion Pharmaceuticals,
please visit www.achillion.com
http://www.globenewswire.com/newsroom/ctr?d=10021101&l=4&a=www.achillion.com&u=http%3A%2F%2Fwww.achillion.com
 or call 1-203-624-7000.

CONTACT: Company Contact:
         Glenn Schulman
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 752-5510
         gschulman@achillion.com
         
         Investors:
         Mary Kay Fenton
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 624-7000
         mfenton@achillion.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.